Home> Products> Inhibitors> Amrubicin-CAS 110267-81-7
price inquiry for CAS:110267-81-7, Product:Amrubicin

Amrubicin CAS: 110267-81-7

Category: Inhibitors
Product Name: Amrubicin
Cat No: I000423
CAS No: 110267-81-7
Synonyms: (7S,9S)-9-acetyl-9-amino-7-[(2S,4S,5R)-4,5-dihydroxyoxan-2-yl]oxy-6,11-dihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
Molecular Formula: C25H25NO9
Molecular Weight: 483.47
SMILES: CC(=O)C1(CC(C2=C(C3=C(C(=C2C1)O)C(=O)C4=CC=CC=C4C3=O)O)OC5CC(C(CO5)O)O)N
Solubility: DMSO:30mg/mL
Target: Topoisomerase
Storage: Store at -20°C
CAS 110267-81-7,Amrubicin
  • Description

Amrubicin(SM-5887) is a novel anthracycline derivative for treatment of bladder carcinoma.
Target: Others
Amrubicin (SM-5887) is an anthracycline used in the treatment of lung cancer. The distribution of SM-5887 in the bladder mucosa and muscular layer was almost equal, but the concentration of its active metabolite, 13-OH derivative, was 5 to 10 times higher in the bladder mucosa than in the bladder muscular layer. The distributions of SM-5887 in the organs other than the bladder, that is, the cortex and medulla of kidney, heart, lung, liver, and spleen, were very low, and those of a 13-OH active metabolite were even lower. In addition, SM-5887 barely affected the normal bladder mucosa. In dogs instilled with 80 mg of SM-5887, no histological change was observed in the bladder mucosa and submucosal layer even after 6-hour retention at the highest concentration of 8,000 micrograms/ml [1]. phase II clinical trial of SM-5887, a new totally synthesized anthracycline derivative, was carried out in 13 patients with inoperable or recurrent gastric cancer. No patient had been given anthracycline previously. SM-5887 was administered by I.V. bolus with a dose of 100 mg/m2 every three weeks. Twelve of 13 cases were eligible and evaluable for the response. Of the 12 evaluated cases, 6 showed no change (NC), including one minor response (MR) [2].

  • References


[1]. Ohmori, H., T. Tsushima, and K. Kobashi, [Experimental studies on intravesical instillation of SM-5887, a novel anthracycline derivative for treatment of bladder carcinoma]. Gan To Kagaku Ryoho, 1996. 23(5): p. 601-6.
[2]. Tsushima, K., et al., [A phase II study of SM-5887 for advanced gastric cancer]. Gan To Kagaku Ryoho, 1991. 18(7): p. 1151-4.


price inquiry for CAS:110267-81-7, Product:Amrubicin